BBNX Beta Bionics Inc Forecast, Technical & Fundamental Analysis
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease... Show more
BBNX is expected to report earnings to fall 30.61% to -34 cents per share on July 29
Q2'26
Est.
$-0.34
Q1'26
Missed
by $0.16
Q4'25
Beat
by $0.08
Q3'25
Beat
by $0.05
Q2'25
Beat
by $0.03
The last earnings report on April 21 showed earnings per share of -49 cents, missing the estimate of -33 cents. With 563.25K shares outstanding, the current market capitalization sits at 755.77M.
A.I.dvisor indicates that over the last year, BBNX has been loosely correlated with IRTC. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if BBNX jumps, then IRTC could also see price increases.
BBNX in downward trend: price expected to drop as it breaks its higher Bollinger Band on June 25, 2026
BBNX broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 12 similar instances where the stock broke above the upper band. In of the 12 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BBNX moved out of overbought territory on June 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 15 cases where BBNX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BBNX turned negative on July 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 24, 2026. You may want to consider a long position or call options on BBNX as a result. In of 20 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BBNX advanced for three days, in of 78 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 62 cases where BBNX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BBNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.786) is normal, around the industry mean (11.208). P/E Ratio (0.000) is within average values for comparable stocks, (65.302). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.948). BBNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (6.761) is also within normal values, averaging (25.206).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
